Mendelian genetic error analysis method based on next-generation sequencing data
Through the Mendel genetic error analysis method based on second-generation sequencing data, the problems of UPD parental source and quality control in NGS sequencing of three core family members were solved, and the accurate distinction of UPD and effective detection of sample quality was achieved, and genetic disease screening was improved Check efficiency and accuracy.
Patent Information
- Application Number
- CN202210305213.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-25
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-03-25
AI Technical Summary
The existing NGS sequencing data analysis method of three-person core family is difficult to accurately distinguish the parental origin of single-parent disome (UPD), and cannot effectively control quality, such as sample confusion and detection of kinship, resulting in genetic disease screening and diagnosis. Inefficient.
Mendel genetic error analysis method based on second-generation sequencing data, by aligning the two-ended 150bp read-length sequences of three-person core families, marking mutation sites, and combining CBS methods to connect points that meet the characteristics into fragments. The distribution of point mutations within the genome-wide, distinguishing between iUPD and hUPD, inferring parental origin and possible sample contamination or kinship inconsistency.
It realizes accurate distinction between UPD parental sources without additional methylation detection, improves the efficiency of genetic disease screening and detection accuracy, enhances the control of sample quality, and improves the analysis ability of second-generation sequencing data.
Smart Images

Figure CN114743596B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of bioinformatics data analysis based on NGS sequencing of a three-person core family, and relates to data analysis of three-person core family whole exome sequencing (Trio-WES) and three-person core family whole genome sequencing (Trio-WGS), and in particular to a Mendelian genetic error analysis method based on second-generation sequencing data. Background Art
[0002] The second-generation sequencing method based on the three-person core family has been widely used in the screening and auxiliary diagnosis of genetic diseases. Uniparental Disomy (UPD) is an epigenetic-related disease, which means that the chromosome fragment from one parent is replaced by the homologous part of the other parent, or the two homologous chromosomes of an individual are from the same parent. The former is called segmental uniparental disomy. Uniparental disomy can be divided into isodisomy UPD (iUPD), the same chromosome from the same parent, and heterodisomy UPD (hUPD), two homologous chromosomes from the same parent.
[0003] UPD is a clinically important disease that accounts for a proportion of the causes of growth failure and endocrine abnormalities. Recent studies have shown that UPD occurs in approximately 1 in 3500 live births.
[0004] Whole exome sequencing (WES) and whole genome sequencing (WGS) have been widely used in the screening and diagnosis of genetic diseases. The detection method of the three-person core family combined with the analysis of the inheritance pattern can improve the detection rate of new mutations and heterozygous mutations. However, there is a lack of basis for the use of the analyzed point mutation data for the analysis of additional types of mutations (such as UPD and its genetic parental origin). For example, different parental sources of chromosome 15 UPD may be associated with different diseases. Maternal deletions lead to Angleman-Syndrome, and paternal deletions lead to Prader-Willi syndrome. There is also a lack of methodological basis for quality control of the number and distribution of sites that do not conform to Mendelian inheritance when using Trio-WES or Trio-WGS, such as inconsistent kinship, whether there is consanguineous marriage, whether there is sample confusion and sample contamination.
[0005] The current methods for analyzing ROH are mainly based on single nucleotide polymorphism array (SNP-array, CMA) analysis of copy number deletion or copy number neutral ROH, but the current methods cannot accurately distinguish the parental origin. If the parental origin is to be distinguished, methylation analysis is usually required. For example, when SNP-array detects chromosome 15, MS-MLPA of the proband and parents in the 15q11.2 region is usually required to determine the parental origin. AutoMap, an analysis tool based on NGS analysis of ROH, is also only used for single sample analysis of iUPD, and cannot analyze hUPD, and cannot do more analysis and quality control. At present, whether the relationship is consistent and whether there is sample contamination or sample confusion is generally compared through STR testing of the core family (Trio). Summary of the invention
[0006] In order to overcome the shortcomings of the prior art, considering that the analysis method based on Trio-WES or Trio-WGS can analyze UPD according to whether the proband has continuous sites that do not conform to Mendelian inheritance; combined with special types of genotypes that do not conform to Mendelian inheritance, it can be used to accurately infer the parental origin of UPD and distinguish iUPD from hUPD; for the situation where there are many large sections of ROH in the whole genome and a certain proportion of the whole genome, it can be used to infer whether the proband has consanguinity homology (IBD); for the sites that do not conform to Mendelian inheritance and their proportions that are evenly distributed in the whole genome, it can be used to indicate whether there is a kinship discrepancy, sample confusion and sample contamination, maternal contamination of prenatal amniotic fluid or abortion product samples, and allogeneic bone marrow transplantation or organ transplantation. The present invention proposes a Mendelian genetic error analysis method based on second-generation sequencing data.
[0007] The present invention provides a Mendelian genetic error analysis method based on second generation sequencing data, comprising the following steps:
[0008] 1) The paired-end 150bp read length of the next-generation sequencing raw sequences of the three core families were aligned to the reference genome to find out the point mutations in the whole genome of the three samples, including single nucleotide polymorphisms (SNPs) and insertions and deletions (InDels);
[0009] 2) Split mutations with more than 2 genotypes into multiple biallelic mutations;
[0010] 3) Filter SNPs and InDel sites with low quality and located in CNV regions with clear pathogenic benign or population polymorphisms;
[0011] 4) marker genotype;
[0012] According to different situations, the mutation sites are marked as denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del respectively; all denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del sites are marked as MIE (Mendelian Inheritance Error);
[0013] 5) Assign denovo, iUPDpat, iUPDmat, MIE, UPDpat, UPDmat, and duo-del the values of 1, 2, 3, 4, 5, 6, and 7 for data visualization, make a distribution map across the whole genome, connect the points that meet certain characteristics into segments using the CBS method, output the segment distribution, and mark the known UPD disease areas;
[0014] 6) Determination of different situations:
[0015] 6.1 If there is a UPD segment in the genome that overlaps with a known UPD disease region, combined with phenotypic analysis, it indicates the possibility of a UPD-related disease; iUPD or hUPD alone may exist, or iUPD and hUPD may exist at the same time, and the parental origin can be determined by combining the marker type;
[0016] 6.2 If there are multiple iUPDs in the genome and they account for a certain proportion of the genome, it indicates the possibility of consanguineous marriage;
[0017] 6.3 If the MIE points are evenly distributed in the genome, but not too dense, there may be sample contamination or maternal contamination of prenatal samples, which indicates the possibility of tumor occurrence for non-prenatal samples;
[0018] 6.4 If the MIE points are evenly distributed throughout the genome and the density is high, and there are many MIE sites, it indicates that there may be sample confusion or inconsistent kinship, or there may be allogeneic organ / bone marrow transplantation.
[0019] According to a preferred embodiment of the present invention, the method of the second generation sequencing in step 1) is Trio-WES or Trio-WGS.
[0020] According to a preferred embodiment of the present invention, in step 1), point mutations in the whole genome of the three samples are found, specifically: based on GATK best practice (http: / / gatk.broadinstitute.org / hc / en-us / sections / 360007226651-Best-Practices-Workflows), a gVCF format file of the point mutation of each sample is analyzed, and then merged into a vcf file using a joint-calling analysis method;
[0021] According to the sample family relationship pedigree file (https: / / www.mv.helsinki.fi / home / tsjuntun / autogscan / pedigreefile.html), the generated vcf file was divided into multiple family vcf files according to the three-person core family, and the sites in each family vcf file that were not detected in the three samples or were all homozygous wild type were filtered out.
[0022] According to a preferred embodiment of the present invention, the step 3) of filtering the sites is specifically as follows:
[0023] Sites on contigs other than 1-22 and chromosomes X and Y were filtered out, and sites with quality values less than 30, maximum genotyping quality less than 20, maximum sequencing depth less than 8, maximum mutant allele frequency less than 0.2, average sequencing depth less than 5, and any sample sequencing depth of 0 or undetected were filtered out.
[0024] Sites with a population frequency > 1% and CNV regions with clear benign pathogenicity or population polymorphism were filtered out.
[0025] 5. According to the Mendelian genetic error analysis method based on second-generation sequencing data, it is characterized in that the step 4) is specifically:
[0026] 4.1 The loci where both the father and mother are homozygous wild type and the proband is heterozygous mutant or homozygous mutant are marked as denovo;
[0027] 4.2 The loci where the father is a homozygous wild type, the mother is a heterozygous mutant type, and the proband is a homozygous mutant type or the father is a homozygous mutant type, the mother is a heterozygous mutant type, and the proband is a homozygous wild type are marked as iUPDmat;
[0028] 4.3 The loci where the mother is homozygous wild type, the father is heterozygous mutant, and the proband is homozygous mutant, or the mother is homozygous mutant, the father is heterozygous mutant, and the proband is homozygous wild type are marked as iUPDpat;
[0029] 4.4 The loci where the mother is homozygous wild type, the father is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDpat;
[0030] 4.5 The loci where the father is homozygous wild type, the mother is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDmat;
[0031] 4.6 The loci where both the father and mother are homozygous mutants and the proband is heterozygous mutant or homozygous wild type are marked as duo-del;
[0032] 4.7 Mark all denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del sites as MIE.
[0033] The present invention mainly solves the problem of using Trio-WES or Trio-WGS second-generation sequencing data to analyze UPD (including iUPD and hUPD) and its parental sources. The parental sources can be determined without the need for additional methylation detection projects such as MS-MLPA. At the same time, it is used to indicate inconsistent kinship, whether there is close relative marriage, whether there is sample confusion and sample contamination, whether there is maternal contamination in prenatal amniotic fluid or abortion product samples, whether there is bone marrow transplantation or organ transplantation and other quality control conditions in combination with actual conditions. It can be used as a routine quality control item in the second-generation sequencing process, and the implicit information in the second-generation sequencing process can be further verified and determined, ultimately improving the positive rate of second-generation sequencing sample detection.
[0034] This method is based on bioinformatics analysis of second-generation sequencing mutations and does not involve experimental modification or optimization. The information provided needs to be further verified using gold standard testing methods and does not represent the final result. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 It indicates that the proband has a severe abnormal clinical phenotype and the copy number is normal but there is a large ROH region in the samples and the MIE analysis results of the parents' whole blood samples as verified by Affymetrix Cyto750K SNParray;
[0036] Figure 2 Indicates the results of MIE analysis of samples of the proband with severe abnormal clinical phenotype and large fragment deletion confirmed by Affymetrix Cyto750K SNParray and whole blood samples of parents
[0037] Figure 3 for Figure 2 The CNV (Copy Number Variation) and VAF analysis results of the samples shown;
[0038] Figure 4 To provide the results of MIE analysis of whole blood samples of a three-person core family whose grandparents were consanguineous through clinical follow-up;
[0039] Figure 5 The results of whole-genome MIE analysis of a pseudo three-person pedigree sample consisting of a phenotypically normal couple and another unrelated normal person.
[0040] Figure 6 The MIE analysis results of the proband's prenatal amniotic fluid and parents' whole blood samples were verified by STR testing to have maternal contamination;
[0041] Figure 7 MIE analysis results of normal phenotypic samples of male probands and normal whole blood samples of their parents;
[0042] Figure 8 Box plot statistical distribution of the total number of MIE loci on all chromosomes in 300 cases (100 Trio core families). DETAILED DESCRIPTION
[0043] The present invention is further described and illustrated below in conjunction with specific embodiments. The embodiments are merely exemplary of the present disclosure and do not define the scope of limitation. The technical features of each embodiment of the present invention may be combined accordingly without conflicting with each other.
[0044] 1. In this example, 300 cases (100 Trio core families) of Trio-WES data output by the double-end 150bp sequencing mode of the BGI T7 model sequencer were aligned to the human reference genome (reference genome version is hg19); (most of them are normal samples, among which the abnormal samples are: 1. The proband is from prenatal amniotic fluid and parental whole blood samples with maternal contamination verified by STR testing, 2. The proband has a serious abnormal clinical phenotype and the copy number is normal but there are large ROH region samples and parental whole blood samples verified by Affymetrix Cyto750KSNParray, 3. There are serious abnormal clinical phenotypes and samples with large fragment deletions verified by Affymetrix Cyto750KSNParray and parental whole blood samples, 4. The whole blood samples of the three-person core family whose grandparents are confirmed to be close relatives through clinical follow-up, 5. A pseudo three-person family sample consisting of a phenotypically normal couple and another normal person who has no genetic relationship);
[0045] 2. Based on GATK best practice (http: / / gatk.broadinstitute.org / hc / en-us / sections / 360007226651-Best-Practices-Workflows), analyze each sample point mutation gVCF format file, and then merge it into a vcf file using the joint-calling analysis method;
[0046] 3. Based on the sample family relationship pedigree file (https: / / www.mv.helsinki.fi / home / tsjuntun / autogscan / pedigreefile.html), we divided the vcf generated in step 2 into multiple family vcf files according to the three-person core family, and filtered out the sites in each family VCF file that were not detected in the three samples or were all homozygous wild type;
[0047] 4. Split mutations with more than 2 genotypes in each family vcf file into multiple biallelic mutations;
[0048] 5. Filter out the sites on contigs other than 1-22 and chromosomes X and Y from each family vcf file, filter out sites with a quality value lower than 30, a maximum genotyping quality lower than 20, a maximum sequencing depth lower than 8, a maximum mutant allele frequency lower than 0.2, an average sequencing depth lower than 5, and any site with a sequencing depth of 0 or no detection in any sample; filter out sites located in CNV regions with a population frequency > 1% and a clearly benign pathogenicity or population polymorphism;
[0049] 6. Classify each pedigree vcf file by marking various loci, and classify the loci that do not conform to Mendelian inheritance;
[0050] Among them, the loci where both the father and mother were homozygous wild type and the proband was heterozygous mutant or homozygous mutant were marked as denovo;
[0051] The loci where the father is homozygous wild type, the mother is heterozygous mutant, and the proband is homozygous mutant, or the father is homozygous mutant, the mother is heterozygous mutant, and the proband is homozygous wild type are marked as iUPDmat;
[0052] The loci where the mother is homozygous wild type, the father is heterozygous mutant, and the proband is homozygous mutant, or the mother is homozygous mutant, the father is heterozygous mutant, and the proband is homozygous wild type are marked as iUPDpat;
[0053] The loci where the mother is homozygous wild type, the father is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDpat;
[0054] The loci where the father is homozygous wild type, the mother is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDmat;
[0055] Loci where both the father and mother were homozygous mutants and the proband was heterozygous mutant or homozygous wild type were marked as duo-del;
[0056] All denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del sites were marked as MIE.
[0057] 7. For each family vcf file, assign denovo, iUPDpat, iUPDmat, MIE, UPDpat, UPDmat, and duo-del values of 1, 2, 3, 4, 5, 6, and 7, and make a distribution map across the entire genome. Use the CBS (circular binary segmentation) method to connect consecutive points that meet certain characteristics into segments, output the segment distribution, and mark the known UPD disease areas;
[0058] 8. If there is no family with too many MIE loci, no further analysis will be performed in this example.
[0059] If there is a UPD segment in the genome that overlaps with a known UPD disease region, then combined with the phenotype, it indicates the possibility of a UPD-related disease, that is, there may be iUPD alone or hUPD alone, or there may be both iUPD and hUPD. The parental origin can be determined by combining the marker type;
[0060] If there are multiple iUPDs in the genome and they account for a certain proportion of the genome, it indicates the possibility of consanguineous marriage;
[0061] If the MIE points are evenly distributed across the genome, but not too dense, there may be sample contamination or maternal contamination of prenatal samples, which may indicate tumorigenesis for non-prenatal samples;
[0062] If the MIE points are evenly distributed throughout the genome and the density is high, and there are many MIE sites, there may be sample confusion or inconsistent kinship, or there may be allogeneic organ (bone marrow) transplantation.
[0063] Figure 1-8 For specific cases. Figure 1 , 2Figures 4, 5, 6, and 7 are the VAF distribution diagrams of the MIE analysis of the six Trios (three-person core families) and their probands. Denovo, iUPDpat, iUPDmat, MIE, UPDpat, UPDmat, and duo-del are represented by square, circle, equilateral triangle, plus sign, cross, diamond, and inverted triangle, respectively, and the corresponding values are 1, 2, 3, 4, 5, 6, and 7. VAF is the abbreviation of Variant Allele Fraction, which is defined as the sequencing depth of the mutant genotype divided by the total sequencing depth of this site. The theoretical value corresponding to the homozygous wild type is 0, the theoretical value corresponding to the heterozygous mutant type is 0.5, and the theoretical value corresponding to the homozygous mutant type is 1. The gray area in the VAF part is calculated by AutoMap (https: / / github.com / mquinodo / AutoMap) software to indicate the possible presence of large ROH regions.
[0064] Figure 1 It means that the proband has a severe abnormal clinical phenotype and the copy number is normal but a large ROH region (chr4:54441842-109664820) is present in the sample and the parents' whole blood samples, and their MIE analysis shows that the chr4:54441842-109664820 region is iUPDmat and the entire chromosome 4 is UPDmat;
[0065] Figure 2 Indicates that the proband has a severe abnormal clinical phenotype and the presence of a large deletion (chr7:114333664-128000091) confirmed by Affymetrix Cyto750K SNParray and the parents' whole blood samples, and their MIE analysis showed that the chr7:114333664-128000091 region is iUPDmat and UPDmat, indicating that the paternal genotype is missing;
[0066] Figure 3 for Figure 2 The CNV (Copy Number Variation) and VAF analysis of the samples shown in the figure showed that there was a deletion of one copy in the chr7:114333664-128000091 region, and the VAF analysis suggested that this region was a ROH region. Figure 2 From the analysis conclusion of MIE, we can infer that there is a 13.7Mb paternal copy number deletion in this sample;
[0067] Figure 4In order to confirm the consanguinity of the grandparents through clinical follow-up, whole blood samples of the three-person core family were collected, and VAF analysis revealed large homozygous regions such as chr11:67395456-84878075, chr11:40106074-48346729, chr11:48388067-56143225, chr19:23676134-30018369, and chr13:102235519-107145829, but the distribution of MIE in these regions was normal;
[0068] Figure 5 The pseudo three-person family sample consisted of a phenotypically normal couple and another normal person with no blood relationship. Whole-genome MIE analysis found that all chromosomes had a very large number of MIE sites, and the VAF distribution was normal, indicating that the family relationship was inconsistent.
[0069] Figure 6 The proband was derived from prenatal amniotic fluid and parents' whole blood samples that were verified to have maternal contamination by STR testing. MIE analysis found that the total number of MIE sites was slightly more than that of normal samples.
[0070] Figure 7 Results of MIE analysis of normal phenotype samples from a male proband and normal whole blood samples from his parents showed few MIE loci and normal VAF distribution.
[0071] Figure 8 Box plot statistical distribution of the total number of MIE sites on all chromosomes of 300 cases (100 Trio core families).
[0072] Table 1: Comparison and classification of specific MIE genotypes of the present invention
[0073]
[0074] Table 1 shows the comparison and classification of the specific MIE genotypes of the present invention. Combined with the results in the chart, it can be seen that Trio-WGS or Trio-WGS data can be used to determine the parental origin of LOH (Loss of heterozygous) in copy number neutrality or copy number loss through the markers of the method of the present invention. In the case of abnormal sex chromosome copy number, this analysis method can also be used to determine which gamete (sperm or egg) has an abnormality.
[0075] Trio-WGS or Trio-WGS data marked by the method of the present invention can be used to analyze whether the parents have consanguineous marriage, sample confusion, family discrepancy, maternal contamination of prenatal samples, etc., and whether the subject has allogeneic organ or bone marrow transplantation.
[0076] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. For ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. A Mendelian genetic error analysis method based on second-generation sequencing data, characterized in that The steps include: 1) The paired-end 150bp read length of the next-generation sequencing raw sequences of the three core families were aligned to the reference genome to find out the point mutations in the whole genome of the three samples, including single nucleotide polymorphisms (SNPs) and insertions and deletions (InDels); 2) Split mutations with more than 2 genotypes into multiple biallelic mutations; 3) Filter SNP and InDel sites in low-quality and benign polymorphic CNV regions; 4) marker genotype; According to different situations, the mutation sites are marked as denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del respectively; all denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del sites are marked as MIE (Mendelian Inheritance Error); 5) Assign denovo, iUPDpat, iUPDmat, MIE, UPDpat, UPDmat, and duo-del the values of 1, 2, 3, 4, 5, 6, and 7 for data visualization, make a distribution map across the whole genome, connect the points that meet certain characteristics into segments using the CBS method, output the segment distribution, and mark the known UPD disease areas; 6) Determination of different situations: 6.1 If there is a UPD segment in the genome that overlaps with a known UPD disease region, combined with phenotypic analysis, it indicates the possibility of a UPD-related disease; that is, it is possible that iUPD or hUPD exists alone, or that iUPD and hUPD exist at the same time, and the parental origin can be determined by combining the marker type; 6.2 If there are multiple iUPDs in the genome and they account for a certain proportion of the genome, it indicates the possibility of consanguineous marriage; 6.3 If MIE sites are evenly distributed across the genome, the total number of MIE sites in the same batch of Trio samples exceeds the 95% quantile, and the total number of MIEs is 5 times greater than the average, there may be sample contamination or maternal contamination of prenatal samples, which indicates the possibility of tumorigenesis for non-prenatal samples; 6.4 If MIE points are evenly distributed throughout the genome, the total number of MIE sites is significantly higher than that of all other types of samples, and is more than three times higher than the total number of MIE samples in the sample contamination or maternal contamination of prenatal samples described in 6.3, it indicates that there may be sample confusion or inconsistent kinship, or there may be allogeneic organ / bone marrow transplantation.
2. The Mendelian genetic error analysis method based on second-generation sequencing data according to claim 1, characterized in that: The method of the second generation sequencing in step 1) is Trio-WES or Trio-WGS.
3. The Mendelian genetic error analysis method based on second-generation sequencing data according to claim 1, characterized in that: In step 1), point mutations in the whole genome of the three samples are found, specifically: Based on GATK best practice, each sample point mutation gVCF format file is analyzed, and then merged into a vcf file using the joint-calling analysis method; According to the sample family relationship ped file, the generated vcf file was divided into multiple family vcf files according to the three-person core family, and the sites in each family vcf file that were not detected in the three samples or were all homozygous wild type were filtered out.
4. The Mendelian genetic error analysis method based on second-generation sequencing data according to claim 1, characterized in that: The step 3) filters the sites, specifically: Sites on contigs other than 1-22 and chromosomes X and Y were filtered out, and sites with quality values less than 30, maximum genotyping quality less than 20, maximum sequencing depth less than 8, maximum mutant allele frequency less than 0.2, average sequencing depth less than 5, and any sample sequencing depth of 0 or undetected were filtered out; Sites with a population frequency > 1% and CNV regions with clear benign pathogenicity or population polymorphism were filtered out.
5. The Mendelian genetic error analysis method based on second-generation sequencing data according to claim 1, characterized in that: The step 4) is specifically: 4.1 The loci where both the father and mother are homozygous wild type and the proband is heterozygous mutant or homozygous mutant are marked as denovo; 4.2 The loci where the father is a homozygous wild type, the mother is a heterozygous mutant type, and the proband is a homozygous mutant type or the father is a homozygous mutant type, the mother is a heterozygous mutant type, and the proband is a homozygous wild type are marked as iUPDmat; 4.3 The loci where the mother is homozygous wild type, the father is heterozygous mutant, and the proband is homozygous mutant, or the mother is homozygous mutant, the father is heterozygous mutant, and the proband is homozygous wild type are marked as iUPDpat; 4.4 The loci where the mother is homozygous wild type, the father is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDpat; 4.5 The loci where the father is homozygous wild type, the mother is heterozygous or homozygous mutant, and the proband is homozygous mutant are marked as UPDmat; 4.6 The loci where both the father and mother are homozygous mutants and the proband is heterozygous mutant or homozygous wild type are marked as duo-del; 4.7 Mark all denovo, iUPDpat, iUPDmat, UPDpat, UPDmat, and duo-del sites as MIE.
Citation Information
Patent Citations
Analyzing method for inheritance mutation mode of trio family on basis of second-generation high throughput sequencing
CN109545281A
Method for determining UPD type, computing device and storage medium
CN112687336A
Method and system for clearing noisy genetic data, phasing haplotype, and reconstructing offspring genome, and use thereof
CN112840404A
Systems and Methods for Identifying Sequence Variation Associated with Genetic Diseases
US20140080718A1
